552c7ae14ClaimWhile targeting direct equity acquisitions and joint ventures with Chinese biotech firms, the U.S. Treasury Department proposal does not explicitly prohibit intellectual property licensing deals commonly conducted by Western pharmaceutical companiesAgreeDisagree
552c7ae14ClaimRaymond James analyst Chris Meekins evaluated the proposed U.S. Treasury rule and stated that intellectual property licensing deals between U.S. pharmaceutical companies and Chinese biotechs will likely remain permissibleAgreeDisagree
552c7ae14ClaimWestern biopharma companies are seeking new drug candidates in China to offset a patent cliff in the early 2030s, when patents on top-selling drugs are set to expireAgreeDisagree
552c7ae14ClaimThe European Union rejected parts of the United Nations pandemic declaration due to explicit red lines regarding intellectual property protections, asserting that technology transfers must remain voluntary and mutually agreed upon.AgreeDisagree
552c7ae14ClaimUnder updated European Union pharmaceutical rules, a company must launch a new medicine within three years if requested by a country or risk losing two years of monopoly rights.AgreeDisagree